Big pharmas face short-term disruption from Japan, but Leerink Swann believes it should be...

|By:, SA News Editor

Big pharmas face short-term disruption from Japan, but Leerink Swann believes it should be "muted relative to other industries.” Of the biggest pharma names, Bristol Myers Squibb (BMY) is the least exposed, while Novartis (NVS) has the most exposure, with 8% of total revenue from Japan. GlaxoSmithKline (GSK) has the most bottom-line exposure.